Ana Dos Santos Rufino

Ms. Ana Dos Santos Rufino

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ARAna Dos Santos Rufino
Ana Dos Santos Rufino
MPMagnus Påhlman
Magnus Påhlman
IOIngrid Olsson
Ingrid Olsson
KHKate Himmelmann
Kate Himmelmann
The aim of this population-based study was to describe the prevalence and characteristics of epilepsy in children with cerebral palsy (CP), focusing on antiseizure medication (ASM) and seizure outcome. Findings were related to CP type, gross motor function and associated impairments. Data on all 140 children with CP born in 2003–2006 were taken from the CP register of Western Sweden. Medical records were reviewed at ages 9–12 and 13–16 years. In total 43% had a diagnosis of epilepsy. Epilepsy was more common in children with dyskinetic CP, who more often had a history of infantile spasms, continuous spike-and-wave during sleep and status epilepticus. Neonatal seizures, severe intellectual disability, severe motor disability and autism were associated with a higher risk of epilepsy. Many children were on polytherapy, and valproate was frequently used, even in girls. At age 13–16 years, 45% of the children with epilepsy were seizure free for at least one year. Onset after 2 years of age, female sex and white matter injury were associated with good seizure outcome. Despite the risk of relapse, reduction or discontinuation of ASM could be an option in selected cases. It is important to optimize ASM and to consider the possibility of epilepsy surgery.

17 February 2025
Verified
Thesis
Open access
PDF file
ARAna Dos Santos Rufino
Ana Dos Santos Rufino
Infantile cerebral palsy (CP) is a chronic neurological disorder comprising heterogeneous subtypes with different clinical symptoms. Structural epilepsy is a common comorbidity, but its prevalence varies greatly between the different CP subtypes. The aim of the present retrospective study was to determine the prevalence and specific characteristics of epilepsy in a population-based CP cohort and to correlate them with different disease-specific and sociodemographic factors. For this purpose, data from the CP register of western Sweden was used. All children born between January 2003 and December 2006 in the county of Västra Götaland in Sweden with confirmed diagnosis of CP were included. Data was manually extracted from the medical records at two predefined time periods, i.e., at the age of 9,0-12,0 years and at the age of 13,0-16,0 years. Of the 140 children initially identified in the registry, two had already deceased before reaching the second inclusion date, leaving a total number of 138 patients (98,6%) in the cohort (43,5% female, 56,5% male). An epilepsy diagnosis was present in 42,8% (n = 59) of patients. Predictive factors for the development of epilepsy were the presence of dyskinetic CP, a positive history of neonatal seizures, a more severe mental or motor disability and the presence of a comorbid autism spectrum disorder. Children with dyskinetic CP were also more likely to have infantile spasms, continuous spike-and-wave discharges during sleep, and status epilepticus compared to other CP subgroups. Almost all patients with epilepsy received anti- seizure monotherapy (45,7%) or polytherapy (45,7%); only 8,5% report of patients did not receive epilepsy-specific therapy. An age of > 2,0 years at epilepsy diagnosis, female gender and imaging evidence of an isolated white matter damage was associated with a more benign course of epilepsy. In summary, epilepsy is a common complication in children with CP, especially in those with a dyskinetic type. Based on this population-based retrospective cohort analysis, further predictive factors for the development of epilepsy as well as for its further complicative or refractory course could be developed. These results may help to improve the care of children with CP and comorbid epilepsy in the future.